Indivior PLC
INDV.L
Indivior PLC
SymbolISINCurrencyExchange
INDV.LGB00BRS65X63GBXLondon Stock Exchange
Advertisement
RNS Number: 6183 W Indivior PLC 18 April 2019 Indivior PLC- Change of Registered Office. Indivior PLC announces that, with immediate effect, the registered office of the Company has been changed to 234 Bath Road, Slough, Berkshire, SL1 4 EE.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5337 W Indivior PLC 17 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Indivior PLC for violations of§§ 10 and 20 of the Securities Exchange Act of 1934 and Rule 10 b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Indivior PLC for violations of§§ 10 and 20 of the Securities Exchange Act of 1934 and Rule 10 b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued...
Gibbs Law Group is investigating claims on behalf of investors of Indivior PLC involving possible securities law violations following news that the US Justice Department filed a lawsuit against Indivior for illegal marketing. Specifically, our investigation focuses on allegations that Indivior and certain of its officers and/or directors may have...
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Indivior PLC resulting from allegations that Indivior may have issued materially misleading business information to the investing public. On April 10, 2019, before the market opened, the US Justice Department charged...
Indivior (INDV) shares have plunged following news that a grand jury in the Western District of Virginia has issued an indictment in connection with a federal criminal investigation initiated by the US Department of Justice in December 2013. The indictment includes twenty-eight felony counts – including one count of conspiracy to commit mail fraud and 22 counts of wire fraud. According to a statement issued by the company, the allegations are based on actions that occurred “almost exclusively prior to Indivior becoming an independent company”; it was demerged from consumer goods giant Reckitt Benckiser (RB.) at the end of 2014. The company strongly denies all allegations. We remain sellers.
Indivior Plc (INDV.L) Announced that on 9 April 2019, a grand jury in the Western District of Virginia issued an indictment in connection with the federal criminal investigation initiated by the Department of Justice in December 2013.
RNS Number: 6881 V Indivior PLC 10 April 2019. Slough, UK, and Richmond, VA, April 10, 2019- Indivior PLC announced that on April 9, 2019 a grand jury in the Western District of Virginia issued an indictment in connection with the federal criminal investigation initiated by the Department of Justice in December 2013.. Key allegations have been contradicted by the...
RNS Number: 5076 V Indivior PLC 09 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
A new study by opioid addiction specialist Indivior (INDV) has revealed that patients who were treated with higher doses of the group’s product Sublocade were more likely to abstain from drug use for longer than those on the lower dose. The latest guidance from the company points to potential sales of Sublocade – a once-monthly injection that provides a sustained level of buprenorphine, Suboxone's active ingredient, in the bloodstream throughout the month – to be between $50m and $70m this year. We remain sellers.
Indivior Plc (INDV.L) Announced that the company presented two new study results at the 50th Annual Conference of the American Society of Addiction Medicine (ASAM) in Orlando, Florida. The data from the first study provides insights into dosing of once-monthly SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use (CIII), for the treatment of moderate to severe opioid use disorder (OUD) in patients who inject opioids, and the second study reports on the impact of therapeutic plasma concentrations of buprenorphine in inhibiting the respiratory depression caused by fentanyl.
RNS Number: 2880 V Indivior PLC 08 April 2019. Slough, UK and Richmond, VA, 8 April 2019- Indivior PLC on Saturday announced data from two new studies: the first provides insights into dosing of once-monthly SUBLOCADE™ injection for subcutaneous use, for the treatment of moderate to severe opioid use disorder in patients who inject opioids, and the second study...
RNS Number: 2873 V Indivior PLC 05 April 2019. Slough, UK and Richmond, VA, 5 April 2019- Indivior PLC today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE™ injection for subcutaneous use for the treatment of moderate to severe opioid use disorder.. ·An 18- month safety study among SUBLOCADE-treated patients...
RNS Number: 0501 V Indivior PLC 04 April 2019. Indivior to Announce First Quarter 2019 Results on May 2nd and Host Conference Call. Slough, UK, and Richmond, VA, 4 April 2019- Indivior PLC today announced that it will release its first quarter 2019 results on May 2 nd at 12:00 BST.
RNS Number: 9954 U Indivior PLC 03 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2080 T Indivior PLC 18 March 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0837 T Indivior PLC 15 March 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Company Profile

Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.

Classification

Market Indices-

Locations

HQ
103-105 Bath Road
SL1 3UH
Slough
Watchlist